Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer
Background: Positron emission tomography (PET) with 16α-[<sup>18</sup>F]-fluoro-17β-estradiol ([<sup>18</sup>F]-FES) can visualize estrogen receptor (ER) expression, but it is challenging to determine the ER status of liver metastases, due to high physiological [<sup>18...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/55c90a5881014d0d86ff8c95e773378a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:55c90a5881014d0d86ff8c95e773378a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:55c90a5881014d0d86ff8c95e773378a2021-11-25T17:20:49ZAnalyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer10.3390/diagnostics111120192075-4418https://doaj.org/article/55c90a5881014d0d86ff8c95e773378a2021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/2019https://doaj.org/toc/2075-4418Background: Positron emission tomography (PET) with 16α-[<sup>18</sup>F]-fluoro-17β-estradiol ([<sup>18</sup>F]-FES) can visualize estrogen receptor (ER) expression, but it is challenging to determine the ER status of liver metastases, due to high physiological [<sup>18</sup>F]-FES uptake. We evaluated whether [<sup>18</sup>F]-FES-PET can be used to determine the ER status of liver metastases, using corresponding liver biopsies as the gold standard. Methods: Patients with metastatic breast cancer (<i>n</i> = 23) were included if they had undergone a [<sup>18</sup>F]-FES-PET, liver metastasis biopsy, CT-scan, and [<sup>18</sup>F]-FDG-PET. [<sup>18</sup>F]-FES-PET scans were assessed by visual and quantitative analysis, tracer uptake was correlated with ER expression measured by immunohistochemical staining and the effects of region-of-interest size and background correction were determined. Results: Visual analysis allowed ER assessment of liver metastases with 100% specificity and 18% sensitivity. Quantitative analysis improved the sensitivity. Reduction of the region-of-interest size did not further improve the results, but background correction improved ER assessment, resulting in 83% specificity and 77% sensitivity. Using separate thresholds for ER+ and ER− metastases, positive and negative predictive values of 100% and 75%, respectively, could be obtained, although 30% of metastases remained inconclusive. Conclusion: In the majority of liver metastases, ER status can be determined with [<sup>18</sup>F]-FES-PET if background correction and separate thresholds are applied.Jorianne BoersNaila LoudiniRobbert J. de HaasAntoon T. M. WillemsenBert van der VegtElisabeth G. E. de VriesGeke A. P. HospersCarolina P. SchröderAndor W. J. M. GlaudemansErik F. J. de VriesMDPI AGarticleFES-PET/CTbreast cancerliver metastasesestrogen receptorquantificationMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 2019, p 2019 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
FES-PET/CT breast cancer liver metastases estrogen receptor quantification Medicine (General) R5-920 |
| spellingShingle |
FES-PET/CT breast cancer liver metastases estrogen receptor quantification Medicine (General) R5-920 Jorianne Boers Naila Loudini Robbert J. de Haas Antoon T. M. Willemsen Bert van der Vegt Elisabeth G. E. de Vries Geke A. P. Hospers Carolina P. Schröder Andor W. J. M. Glaudemans Erik F. J. de Vries Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer |
| description |
Background: Positron emission tomography (PET) with 16α-[<sup>18</sup>F]-fluoro-17β-estradiol ([<sup>18</sup>F]-FES) can visualize estrogen receptor (ER) expression, but it is challenging to determine the ER status of liver metastases, due to high physiological [<sup>18</sup>F]-FES uptake. We evaluated whether [<sup>18</sup>F]-FES-PET can be used to determine the ER status of liver metastases, using corresponding liver biopsies as the gold standard. Methods: Patients with metastatic breast cancer (<i>n</i> = 23) were included if they had undergone a [<sup>18</sup>F]-FES-PET, liver metastasis biopsy, CT-scan, and [<sup>18</sup>F]-FDG-PET. [<sup>18</sup>F]-FES-PET scans were assessed by visual and quantitative analysis, tracer uptake was correlated with ER expression measured by immunohistochemical staining and the effects of region-of-interest size and background correction were determined. Results: Visual analysis allowed ER assessment of liver metastases with 100% specificity and 18% sensitivity. Quantitative analysis improved the sensitivity. Reduction of the region-of-interest size did not further improve the results, but background correction improved ER assessment, resulting in 83% specificity and 77% sensitivity. Using separate thresholds for ER+ and ER− metastases, positive and negative predictive values of 100% and 75%, respectively, could be obtained, although 30% of metastases remained inconclusive. Conclusion: In the majority of liver metastases, ER status can be determined with [<sup>18</sup>F]-FES-PET if background correction and separate thresholds are applied. |
| format |
article |
| author |
Jorianne Boers Naila Loudini Robbert J. de Haas Antoon T. M. Willemsen Bert van der Vegt Elisabeth G. E. de Vries Geke A. P. Hospers Carolina P. Schröder Andor W. J. M. Glaudemans Erik F. J. de Vries |
| author_facet |
Jorianne Boers Naila Loudini Robbert J. de Haas Antoon T. M. Willemsen Bert van der Vegt Elisabeth G. E. de Vries Geke A. P. Hospers Carolina P. Schröder Andor W. J. M. Glaudemans Erik F. J. de Vries |
| author_sort |
Jorianne Boers |
| title |
Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer |
| title_short |
Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer |
| title_full |
Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer |
| title_fullStr |
Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer |
| title_full_unstemmed |
Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer |
| title_sort |
analyzing the estrogen receptor status of liver metastases with [<sup>18</sup>f]-fes-pet in patients with breast cancer |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/55c90a5881014d0d86ff8c95e773378a |
| work_keys_str_mv |
AT jorianneboers analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT nailaloudini analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT robbertjdehaas analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT antoontmwillemsen analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT bertvandervegt analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT elisabethgedevries analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT gekeaphospers analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT carolinapschroder analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT andorwjmglaudemans analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer AT erikfjdevries analyzingtheestrogenreceptorstatusoflivermetastaseswithsup18supffespetinpatientswithbreastcancer |
| _version_ |
1718412471617716224 |